department of Dhaka Medical College, Dhaka from November, 2007 to April, 2008 with the history (symptom and sign) compatible with Kala-azar.The cases were confirmed by the presence of Leishmania Donovan (LD) bodies on splenic smear. All of them received full course of Anti-leishmanial (Cap.Miltefosine) treatment before presented to us. We diagnosed them as treatment unresponsive to Miltefosine as all the relapse occurred with in one year of completion of initial treatment. They were treated with Inj.Stibogluconate and Inj.Amphotericin-B with successful outcome (clinical and parasitological cure).The cases were analyzed meticulously to see the age and sex distribution of the patient along with clinical feature, laboratory findings and lag period between completion of initial treatment and reappearance of symptoms. All the observations have been presented in this paper.
Results:
Out of seven patients four were male and three female. Their age ranged from 4 to 35 years (Table I) . On admission most common features were Fever(7),Loss of weight (5),Loss of appetite (4),Abdominal mass (4),Anemia (7),Hepatomegaly 1 In Bangladesh a multicentric Phase IV clinical trial was also conducted. The result of this trial is yet to be published. In this case series we encountered seven patients during the last ten months who were treated with full course of capsule Miltefosine but failed to respond. Relapse occurred in all cases with in two to nine months. According to our national guideline we noted all the cases as treatment failure to Miltefosine as it happened with in one year of completion of therapy. 5 Oral miltefosine has a direct leishmanicidal property and is not dependant on host immune response. Though miltefosine is the only oral effective agent against VL, its long half life of about 150 hours may create problem of resistance and relapse when used indiscriminately as monotherapy. 1 Miltefosine resistant lines of L. donovani promastigotes have been generated in the laboratory. Mechanism of resistance is due to defective uptake of miltefosine through point mutations on a plasma membrane aminophospholipid translocase. 1 Recently National Kala azar Elimination Program has advocated miltefosine as the first line drug for the treatment of kala azar in Bangladesh. 5 But it is still debatable whether this drug can replace SSG as first line drug for Bangladesh as there was no such data or research work done in Bangladesh before regarding decreasing efficacy of Sb. It is also noticeable that five (5) patients out of seven (7) in this case series were successfully treated by this drug. Rests of the two patients were treated with Amphotericin-B. This drug now extensively used in India and primary unresponsiveness and relapses were uncommon though recently unresponsiveness to Liposomal Amphotericin was noted in some Sudanese patient. 13 So in near future treatment of Kala-azar will be a great challenge for the physicians.Immidiate future strategies should be to save two new potent antileishmanial drugs, Miltefosine and Paromomycine acquiring resistance in VL. To solve the problem of resistance, relapses and to reduce the length of treatment, combination of two antileishmanial drugs might be the desirable solution. Researcher of our country should come forward to make extensive study and find out the best possible combination.
